Last updated on August 2019

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney


Brief description of study

A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of ANG-3777 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney.

The major objective is to demonstrate the safety and efficacy of ANG-3777 in reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor renal allograft.

Clinical Study Identifier: NCT02474667

Find a site near you

Start Over

UCLA Medical Center

Los Angeles, CA United States
  Connect »

Keck Hospital of USC

Los Angeles, CA United States
  Connect »

UC Davis Medical Center

Sacramento, CA United States
  Connect »

Tampa General Hospital

Tampa, FL United States
  Connect »

Rush University

Chicago, IL United States
  Connect »

Northwestern University

Evanston, IL United States
  Connect »

Kansas University

Lawrence, KS United States
  Connect »

University of Louisville

Louisville, KY United States
  Connect »

Barnes-Jewish Hospital

Saint Louis, MO United States
  Connect »

University of Cincinnati

Cincinnati, OH United States
  Connect »

University of Pennsylvania

Philadelphia, PA United States
  Connect »

Houston Methodist Hospital

Houston, TX United States
  Connect »

University of Virginia

Charlottesville, VA United States
  Connect »

Medical College of Wisconsin

Milwaukee, WI United States
  Connect »